Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Current Assets (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Current Assets for 6 consecutive years, with $101.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets rose 324.73% year-over-year to $101.1 million, compared with a TTM value of $101.1 million through Dec 2025, up 324.73%, and an annual FY2025 reading of $101.1 million, up 324.73% over the prior year.
  • Current Assets was $101.1 million for Q4 2025 at SAB Biotherapeutics, down from $113.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $113.3 million in Q3 2025 and bottomed at $770615.0 in Q3 2021.
  • Average Current Assets over 5 years is $31.6 million, with a median of $23.0 million recorded in 2022.
  • The sharpest move saw Current Assets soared 3218.15% in 2022, then tumbled 85.9% in 2023.
  • Year by year, Current Assets stood at $50.2 million in 2021, then crashed by 55.97% to $22.1 million in 2022, then skyrocketed by 166.58% to $58.9 million in 2023, then tumbled by 59.61% to $23.8 million in 2024, then surged by 324.73% to $101.1 million in 2025.
  • Business Quant data shows Current Assets for SABS at $101.1 million in Q4 2025, $113.3 million in Q3 2025, and $9.3 million in Q2 2025.